The External Assessment Centre excluded all the studies identified by the sponsor because they were outside the scope of the evaluation, although it did recognise that the studies contained useful ...
Please provide your email address to receive an email when new articles are posted on . More than 72% of patients were either somewhat or very satisfied with their treatment outcomes. Over 84% of ...
VALENCIA, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care ...
The Food and Drug Administration signs off on a new wound treatment device by Avita Medical. Tech: Avita's Recell. Valencia-based Avita Medical Inc. has received FDA approval for a version of its ...
BATON ROUGE, La. (WAFB) - Burn surgeons at Baton Rouge General are using a new spray-on skin technology on nearly every burn patient, making the healing process faster and less painful while reducing ...
VALENCIA, Calif. and MELBOURNE, Australia, June 07, 2023 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization ...
AVITA Medical Highlights Largest Real-World Analysis Demonstrating Reduced Hospital Stay with RECELL
VALENCIA, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today highlighted ...
In its second approval this month from the U.S. FDA, Avita Medical Inc.’s Recell system received premarket approval for the repigmentation of stable depigmented vitiligo lesions. The approval marks ...
VALENCIA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback